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Abstract: Čerenkov radiation is a fascinating optical signal, which has been 
exploited for unique diagnostic biological sensing and imaging, with 
significantly expanded use just in the last half decade. Čerenkov 
Luminescence Imaging (CLI) has desirable capabilities for niche 
applications, using specially designed measurement systems that report on 
radiation distributions, radiotracer and nanoparticle concentrations, and are 
directly applied to procedures such as medicine assessment, endoscopy, 
surgery, quality assurance and dosimetry. When compared to the other 
imaging tools such as PET and SPECT, CLI can have the key advantage of 
lower cost, higher throughput and lower imaging time. CLI can also provide 
imaging and dosimetry information from both radioisotopes and linear 
accelerator irradiation. The relatively short range of optical photon transport 
in tissue means that direct Čerenkov luminescence imaging is restricted to 
small animals or near surface human use. Use of Čerenkov-excitation for 
additional molecular probes, is now emerging as a key tool for biosensing 
or radiosensitization. This review evaluates these new improvements in CLI 
for both medical value and biological insight. 
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1. Introduction 
In just the past six years, a renaissance of sorts has occurred in the interest of applying 
Čerenkov light emission to the application of biomedical molecular imaging and therapy. 
There has been rapid development of tools and different applications in this field. This review 
charts some of the key areas being developed, translating the use of Čerenkov light from a 
curious phenomenon into a unique probe of radiation dose and tissue function. 
Čerenkov radiation (CR) was observed for the first time about one century ago, from a 
charged particle emitting visible light from moving through a dielectric medium at a speed 
greater than the velocity of light in that medium [1, 2]. After the first observations, Pavel 
Čerenkov proposed a report on production of the luminescence radiation by high speed 
Compton electrons, which are produced by gamma radiation. Further studies by Ilya Frank 
and Igor Tamm showed that the observed light is produced by charged particles moving in the 
matter with velocity greater than the phase velocity of light in that medium, leading to the 
Nobel Prize for these three, in 1958. Since this time, Čerenkov has been used in many areas 
of physics to detect charged particles [3, 4] and their motion, and to measure unique 
phenomena [5–7]. 
Research in biological radioisotope use took advantage of the availability of highly 
sensitive Charged Coupled Device (CCD) cameras previously set up for bioluminescence 
imaging, and this has allowed widespread use of Čerenkov as a tool for different types of 
imaging, even if present at very low levels. Beyond simply imaging the CR, there has been a 
substantial amount of activity using CR as an excitation source for biomolecules, in 
Čerenkov-excited luminescence imaging (CLI). CLI extends the scope of this imaging well 
beyond direct Čerenkov, because it provides detection of signals which have much longer 
tissue penetration, but can be used to report on the Čerenkov deeper inside the tissue. 
Applications include a very wide range such as in-vivo beta and alpha radionuclide emitter 
quantification [8–14], intraoperative or endoscopic imaging [15, 16], small animal 
tomographic imaging [10, 12, 17–20], radiation dose imaging in water phantoms and tissue 
[21], and high resolution molecular sensing in vivo [9, 22]. Each of these applications is 
discussed here, after the first two sections outlining Čerenkov radiation principles and the 
general development of CLI as a modality. 
2. Čerenkov radiation principles 
The results of several observations shows that molecules of a dielectric are polarized by 
moving a charged particle through the dielectric and when these polarized molecules return to 
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their ground state, they emit light photons and in fact the absorbed energy will be emitted as 
luminescence radiation [9]. In other words, Čerenkov radiation is induced when a charged 
particle moves faster than light velocity in vacuum divided by refractive index of 
environment (c/n). Therefore, the intensity of Čerenkov radiation is related to the velocity and 
energy of the particles and the refractive index of environment. So, there would be a threshold 
condition for production of CR: 
 1nβ >  (1) 
Where n is refractive index and β is a relativistic phase velocity: 
 
2
2
11
1E
mc
β
  
= −   +  
 (2) 
According to Eq. (1) & (2), the required threshold energy for production of CR is given by: 
 2
2
1 1
11
min mc
n
E
   = − 
−  
 (3) 
This threshold energy for an electron in water with refractive index of 1.33 is 0.264 MeV 
and for tissue using a refractive index of 1.4, is 0.219 MeV. 
Many of the used beta emitter radionuclides used in medicine, including all of positron 
emitter radionuclides used in PET, have greater energy than threshold energy, therefore, they 
can produce Čerenkov photons in water and tissue [23–25]. Because of the low energy of 
secondary electrons from Compton scattering or photoelectric interaction between tissues and 
gamma particles gamma emitter radionuclides, can’t produce Čerenkov emission [26–29]. 
Also, the alpha emitter radionuclides, can’t provide threshold conditions to produce Čerenkov 
photons [29, 30]. The production of CR by 225Ac , which is an alpha emitter, has been 
demonstrated, but this may be due to production of beta particles by daughter nuclei from 
225Ac  such as 213Bi . 
Mitchell et al., showed the threshold energy of charged particles to produce CR in an 
environment relates to the medium refractive index [31]. This is also indicated in Eq. (3). 
Also, it has been shown that the intensity of produced photons increases with the refractive 
index [9, 10, 12–14, 32]. This fact leads to difference in production of CR in different tissues. 
As the tissues refractive indecies are widely variable, so the produced photons have different 
intensity. High energy charged particle emitter radionuclides are less sensitive to the 
differences of refractive index, therefore, there are smaller difference in intensity of the 
produced radiation from these kinds of radionuclides. 
CR intensity is related to the type of the radionuclide and its activity. Frank and Tamm 
predicted the number of emitted photons with wave length between 1λ  and 2λ ( 1 2λ λ< ) per 
electron by presenting an equation: 
 2 2
1 2
2 1 1 11
137
dN
dx n
π
λ λ β
  
= − −    
 (4) 
The Frank-Tamm relationship shows that increasing particle energy leads to an increasing 
rate of emitted photon and light radiation. 
#242296 Received 2 Jun 2015; revised 15 Jul 2015; accepted 16 Jul 2015; published 28 Jul 2015 
(C) 2015 OSA 1 Aug 2015 | Vol. 6, No. 8 | DOI:10.1364/BOE.6.003053 | BIOMEDICAL OPTICS EXPRESS 3057 
3. Čerenkov luminescence imaging (CLI) 
In recent years, imaging of weak CR photons is possible thanks to improvements in optical 
imaging and increasing the sensitivity of CCD cameras. The idea of CR imaging using CCD 
cameras was presented by Cho et al. for the first time [33]. Then, in 2009, reports based on 
CR imaging of some PET radionuclides (such as 13N  and 18F ) and SPECT ( 99mTc  and 131I ) 
and radiotherapy ( 90Y ) indicate the ability of CR imaging to show the radioactivity 
distribution in vivo (see Fig. 1) [8, 12, 14]. These studies led to creation of a modern method 
of optical imaging in which images are generated by emitted Čerenkov photons produced by 
high energy charged particles. This new imaging has been referred to as Čerenkov 
Luminescence Imaging (CLI). However it is important to recognize that the luminescence in 
this name refers to the Čerenkov light itself, and not anything induced by it, which will be 
later referred to as Čerenkov excited luminescence. 
Conventional nuclear imaging method such as PET and SPECT are used widely in 
molecular imaging, but these methods have some problems such as high cost, limited 
availability, low spatial resolution and the fact that they are time-consuming [34]. CLI, as a 
modern technique which connects optical imaging to radionuclide imaging, largely solves 
mentioned problems of PET and SPECT and in addition, CLI has relatively high sensitivity 
when the light is not attenuated by tissue. Since 2009 CLI has many applications in 
preclinical studies [35, 36]. and CLI will have clinical applications. 
Most positron emitter radionuclides used in the clinic, have higher energy than required 
for the threshold energy to produce CR. PET radionuclides such as 18F , 15O , 13N , 11C , 64Cu , 
124I  are examples of these types of radionuclides, with different CLI yields as illustrated in 
Fig. 1. Many studies have been conducted for in-vivo imaging of these radionuclides 
distribution [13, 37–42]. The results of these studies indicate that the obtained data from 
Čerenkov radiation detection shows a good agreement with PET imaging results. Therefore, 
similar to PET, CLI can be considered as a reliable technique in biological researches. 
 
Fig. 1. The relative CLI yield for different isotopes is shown in top left [13], and one of the 
first images observed from a mouse using CLI [8]. Soon after this, the first CLI image from a 
human was taken, shown (right-top) and its fusion on photographic image of the patients neck 
(right-bottom) to show the location of the intensity in the thyroid [53]. 
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Beta emitter radionuclides are good choices for use in clinical applications for dose 
delivery because of the electron low penetration depth, but direct imaging of the distribution 
and absorption of the labeled radiopharmaceutical is not possible with PET nor SPECT. 
Therefore, CLI can be a suitable technique for imaging of these radionuclides. Many studies 
have been done in Čerenkov luminescence imaging of beta emitter radionuclides such 
as 131I , 90 32 198,  ,  Y P Au  [43–48]. Results of these studies indicate that it is possible to increase 
the spatial resolution of SPECT images using CLI. In addition to the mentioned 
radionuclides, the use of CLI in spectroscopy and measurement of delivered dose by 
secondary electrons produced by megavoltage photons has been taken into consideration in 
recent years [49–51]. 
Also, several studies have been conducted using this technique for clinical imaging of the 
human body. Spinelli et al. used CLI for thyroid imaging for the first time [52, 53]. By fusion 
of optical images on CLI images of a patient who was treated with 131I , they demonstrated 
that, it is possible to generate two-dimensional images from superficial organs (Fig. 1). 
Some of the recently developed extensions to CLI in medicine are introduced in the 
following sections, describing both animal and human applications, where in some cases the 
signal is Čerenkov luminescence itself, and in some cases it is Čerenkov-excited 
luminescence from secondary molecules. 
4. Čerenkov luminescence endoscopy (CLE) 
Endoscopy has an important role in diagnosis of gastrointestinal diseases but, as endoscopy 
generates only anatomical images (not functional), it is not possible to identify the difference 
between similar anatomical diseases and abnormalities and also recognize the border between 
tumor and normal tissue. So, combination of anatomical and functional imaging techniques is 
important in surgery and diagnosis of cancer. 
It has been shown that, it is possible to detect the organs within the body by using optical 
fibers and a CCD camera [54], as well as enable endoscopic testing [55, 56]. These studies 
led to introduction of CLE systems which have apparently high sensitivity and resolution and 
consist of an optical fiber connect to a CCD sensitive camera which can be used as a helpful 
tool during the cancer surgery [16] (Fig. 2). 
Using the combination of Čerenkov endoscopy images and common endoscopy, CLE can 
be used to determination of diseased tissues and monitoring during surgery [16]. Also, this 
system can be used to image the organs such as bladder which typically appear as a dark hole 
with Čerenkov imaging. 
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 Fig. 2. Comparison between CLE and IVIS optical imaging system is shown, using before 
surgery (left) and after surgery (right) to illustrate how residual tumor could be detected by 
CLI, extending nuclear medicine imaging to an optical surgical setting [16]. 
One of the advantages of CLE is having higher spatial resolution than PET and SPECT. 
This resolution depends on imaging system, the number of beta particles in tissue, and light 
scattering of the tissue. Combination of CLE and PET images can be helpful for exact 
determination of location of the tumor. 
5. Čerenkov luminescence tomography (CLT) 
The idea of generating tomographic images using CR was initially presented by Li et al. [12], 
where they compared three-dimensional reconstructed images to PET images and found an 
agreement between the CLT and PET images in distributions of radiation, but the resolution 
of the CLT images was much lower than the PET images due to the high degree of light 
photon scattering in CLT. 
Zhong et al., decreased the reconstruction images errors using anatomic information of 
imaged animals [18]. Also, Hu et al., fused CLT images with micro-CT and SPECT images 
of experimented animals and showed that there was an acceptable difference between SPECT 
images and reconstructed images of CLT. They suggested that CLT optical imaging could be 
used for validation of SPECT imaging [10]. They, also, increased the quality and resolution 
of the images using the CT and SPECT images in reconstruction of CLT [20, 45]. 
These studies emphasize the possibility of using CLT for in-vivo determination of 
radioactivity distribution [15, 18, 19]. Some advantages of the CLT technique are low cost 
and the available facilities for the procedure. However, considering the weak level of 
Čerenkov intensity and the possibility of scattering and absorption of CR within tissue, extra 
care is required to deal with these exceptionally low light signal levels. Additionally, solving 
the non-linear inversion problem with an ill posed problem is complicated and the use of prior 
information is likely required for linear response of the signal. Still, there is robust activity in 
the area of developing CLT as a reliable method for imaging radiation sources within mice. 
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 Fig. 3. Čerenkov luminescence tomography (CLT) is demonstrated in a mouse model with 
uptake in the heart and bladder shown (a) & (b) and compared to that of the gamma signals 
detected and reconstructed by PET (c) & (d) [12]. 
6. Čerenkov luminescence imaging dosimetry (CLID) 
In recent years, spectroscopy of Čerenkov radiation produced by a clinical linear accelerator 
(LINAC) has been examined [57–59] in radiation therapy. The CR intensity increases sharply 
with particle energy above the threshold energy, and LINACs generally operate in the 6 to 18 
MeV range, delivering predominantly photons in most treatments (80 + %) or electrons 
(<20%). So the optical emission per each particle from a linear accelerator is almost 2-3 times 
greater than that from beta emitter radionuclides in the <1MeV range [48]. So, the intensity of 
obtained signal from CR spectroscopy in radiotherapy is high and can be used for monitoring 
of the treatment with a carefully designed detection system. 
In radionuclide spectroscopy, it is typically possible to provide a closed environment with 
no light inside. But in the case of a linear accelerator, providing this environment is not 
possible. Therefore, Glaser et al. presented a time-gated method to obtain the signal 
measurement [60]. They succeeded in decreasing the effect of ambient light by 1000 times by 
synchronizing the acquisition by CCD camera to the linear accelerator microsecond pulses 
[57]. 
Since 2011, this research has been carried out by focusing on using CR for radiation 
dosimetry of linear accelerator photons. Imaging of CLID was demonstrated for generation of 
the dose profile of delivered photon beams in a water phantom [30, 61]. Through addition of a 
fluorophore to the water, the Čerenkov emission stimulates fluorescence and the imaged 
signal is an indirect reporter, with the fluorescence process randomizing the directions away 
from the cone of light generated by the Čerenkov process. This approach has several 
advantages in comparison to the other more commonly used techniques in radiation therapy 
dosimetry. Some of these advantages are it being wide field, high resolution and faster than 
the typical single channel ionization chamber methods or gel dosimetry. In addition, CLID 
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doesn’t require any reading mechanism and doesn’t change with time, and so has some 
implicit advantages for certain types of dosimetry questions. 
 
Fig. 4. The experimental results (left) and schematic (right) of the Čerenkov dosimetry 
imaging system, acquiring 2D projection views, and used for 3D reconstruction filtered 
backprojection imaging of the images [21]. The square MegaVolt photon beam profile (top 
left) and the complex beam profile (bottom right), were tomographically imaged with the 
camera, and the sonogram data reconstructed with filtered back projection. 
Through imaging from a range of rotational angles, the data can be reconstructed from 
filtered backprojection imaging, to generate three-dimensional images of dose profiles in the 
water phantoms [21], as shown in Fig. 4. These three dimensional images provide the 
possibility of a greater understanding of transferred energy by radiation in water phantom 
(Fig. 3), and can be used for large fields of view with still relatively high spatial resolution, 
and faster 3D acquisition than with any other current dosimetry tool. 
Recently, Glaser et al. completed a more exhaustive study comparing CR to absorbed 
dose of mega voltage photon, electron and proton beams using Monte Carlo analysis. They 
concluded that for X-ray photons, CR is suitable in stereotactic radiation therapy and surgery 
validation studies for verification of IMRT treatment in water phantom, near monoenergetic 
sources (such as cobalt-60 and brachytherapy sources) and also, for measurement of 
superficial dose [30]. For electron therapy, using CR is suitable just for superficial dosimetry 
[62] and interestingly for proton therapy this technique seems to have limited value due to the 
lack of CR at the Bragg peak. 
In 2013, studies to estimate the superficial dose in a tissue equivalent phantom were 
completed [38, 37]. In these studies, X-ray and electron beams from a LINAC were examined 
with profile imaging and tomography. This technique, unlike the other superficial dosimetry 
techniques such as radiochromic films, ionization chamber, MOSFET, diodes and TLDs, 
would not require the dosimeter near or on the surface of the body, since all patients emit 
these photons during the radiotherapy treatment. Additionally it is high spatial resolution (less 
than a millimeter) while most of the other dosimetry techniques, have lower resolution or 
sparse sampling points. The resolution of film dosimetry is similar to this, but its procedures 
physically limited in space and time. 
Zhang et al. presented a report based on first superficial dosimetry by CR during exposure 
with linear accelerator in vivo [50]. They showed CR intensity of tissue-equivalent phantom 
#242296 Received 2 Jun 2015; revised 15 Jul 2015; accepted 16 Jul 2015; published 28 Jul 2015 
(C) 2015 OSA 1 Aug 2015 | Vol. 6, No. 8 | DOI:10.1364/BOE.6.003053 | BIOMEDICAL OPTICS EXPRESS 3062 
irradiation have relation with transferred dose. Also, by superficial dosimetry of oral tumor of 
a dog during radiation treatment. 
These studies led to video imaging of CR during surgery of patient with breast cancer, 
Fig. 5 [61, 63]. This video imaging showed that, using this method for imaging of superficial 
dose of treatment region during the exposure, technologists can ensure the precision 
positioning of patient and suitability of instruments used for exposure (MLCs and wedges, 
shown in a of Fig. 5) and also, three-dimensional dose conformity. One of important features 
of this technique is the possibility of dosimetry during the exposure and observation by the 
treatment team in the control room. 
Existing problems in estimating superficial dose and complex modeling due to 
dependence on factors such as energy, field size, blocks, source-skin distance, radiation angle 
and uncertainty of delivered dose, always cause challenges for superficial dose estimation. 
CLID could lead to improve wide field superficial dosimetry once fully developed, because of 
the value in being able to image in real time and visualize entire tissue surfaces being 
irradiated [51]. 
 
Fig. 5. A sequence of images of the breast treated with a dynamic wedge radiotherapy plan, 
where the beam shape changes with time, showing the sequence of beam shapes formed by the 
multi-leaf collimator (a) and (b), and frames from the Čerenkov video sequence of the 
treatment (c) [52, 53]. 
7. Čerenkov emission luminescence scanned imaging (CELSI) 
The natural combination of CLID and CLI is the concept of using targeted radiation beams to 
introduce Čerenkov into tissue for the purpose of exciting molecular probes and optically 
detecting the signal, as a way to precisely measure the microenvironment. This was 
demonstrated with tomographic imaging [64] and scanned imaging recently [22]. The concept 
of Čerenkov excitation to induce luminescence and scan the imaging (CELSI) [22] can be 
used to excite phosphorescent probes, which report on signals such as pH or oxygenation in 
the tissue, or could be used with fluorescent probes tagged to proteins that report on 
localization to receptors or enzymatic function. 
The CELSI concept was recently demonstrated in vivo with a rat injected with 
luminescent oxygen probe reporter in one lymph node,. The resulting image was 
superimposed on an x-ray scan of the animal and is shown in Fig. 6(c) below. The compelling 
part of this work is the realization that this could be done at diagnostic radiation doses (here 
done with 0.02 cGy) and that it allows for high resolution scanning down to a few centimeters 
of tissue. The resolution improvement is shown in Fig. 6(b) relative to the diffuse scan in (a). 
In traditional optical imaging diffusion of the light in tissue is inevitable, and so the loss of 
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spatial resolution after a few millimeters. However the CELSI scan, Fig. 6(b) shows near 
complete preservation of the lines scan resolution from 0mm depth down to 17mm of depth 
into a tissue phantom. 
 
Fig. 6. Čerenkov excited luminescence scanned imaging is demonstrated in tissue phantoms, 
with line-scan data from a luminescent line source in varying depths of Intralipid shown in (a) 
and (b) with diffuse illumination in (a) and scanned CELSI imaging in (b) illustrating the 
improvement in spatial resolution. The raster line scan of a mouse with luminescence in one 
lymph node is shown in (c), with a total body dose of 0.02 cGy [22]. 
Future work on CELSI or related imaging principles could lead to a technique for high 
resolution molecular imaging in rodents or humans. The issues to be resolved are the limits to 
depth, concentration and radiation dose required for sufficient signal to noise, and to 
determine the relative benefits of different molecular probes used in this setting. 
8. Molecules for Čerenkov sensing and radiosensitization 
The concept of using Čerenkov light to excite molecules in tissue has been discussed for over 
a decade [65], but it has just recently been applied to tissue imaging and therapy [9, 66]. 
While the intensity of Čerenkov is very low, in the nanoWatt to picoWatt range, the choice of 
radiation source and the duration has a large effect upon what is possible. 
The imaging concept has two different applications, basically 1) to use the fluorophore to 
report on the radiation activity concentration, by having coupled radiation and optical emitters 
[62], or 2) to use the radiation as a source of Čerenkov which activates a biomolecular probe 
within the tissue, that reports on the tissue microenvironment [67]. The former application is 
interesting but is likely limited to pre-clinical work given the nature of a hybrid radiation-
optical probe, and may ultimately have limited impact in the field. Still, as new therapies 
involving injectable isotopes emerge, the need to better understand biodistribution and the 
heterogeneity of dose will be important, and it is possible that Čerenkov mediated dose 
quantification could have value. The complication in this issue is the known threshold dose 
for Čerenkov emission, and how this may limit the linearity between optical signal and the 
actual dose. In vitro use is well established though, and likely very strong potential. As can be 
seen from the previous CELSI section, the second application of molecular sensors in tissue 
could have a very wide impact on the field of biochemical sensing in situ or in vivo, and 
simply requires careful consideration around the scanning approach used. 
Sensing of oxygenation in tissue has been demonstrated [64, 68], and sensing of pH with 
probes is also possible [69]. The examination of idealized probes for sensing depends a bit on 
the type of radiation used (Beta emitters, vs Gamma, external source vs. internal source, etc). 
This field is at an embryonic stage, and while the actual uses are likely to be in niche areas, 
the amount of physical chemistry research appears to be growing. 
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Enhancement of the Čerenkov signal is possible via interaction with radiation absorbing 
media, such as gold or copper based nanoparticles [70–72]. Several innovative designs in 
nanoparticle material science have shown that a carefully designed particle can enhance the 
signal, or this effect could be used for microenvironment sensing [73]. The self illuminating 
version of these, can be used for combined PET and NIR imaging, or be used for radiotherapy 
in situ with the potential for NIR imaging of the delivery. 
Radiosensitization is a field which has been developed for many decades, with well 
established methods for achiving this. However it was just recently that the use of 
nanoparticles to enhance sensitization via Čerenkov excitation has been demonstrated [66]. 
This has very interesting potential for further development and when the pharmacology and 
toxicology issues of their use are worked out, there could be important applications for these 
type of nanoparticles as Čerenkov based radiation sensitizers. 
9. Conclusion 
In summary, the use of Čerenkov radiation in biomedical imaging has seen some major 
innovations in recent years. These studies indicate that CLI has growing interest in use for 
preclinical research in the field of nuclear medicine, to map dynamic radioactivity 
distributions which are usually performed by SPECT/PET imaging systems. CLI could 
provide quantitation of radiotracer absorption in humans especially in the case of superficial 
tumors and as a helpful instrument in endoscopy during surgery. This technique can also be 
used for quality assessment and dosimetry of clinical linear accelerators. This procedure has 
advantages such as lower cost and less time consuming for imaging than other similar 
techniques for instance PET and SPECT. The potential for innovative new biochemical 
sensing methods and radiosensitization approaches is very exciting, and these areas are just 
emerging now. 
Despite the large number of case studies in CLI, still there are challenges and limitations 
in application of this technique. The challenges include the exceptionally weak intensity of 
the optical signal, in the nanoWatt to picoWatt per cm2 range typically. Also the relatively 
low penetration depth of some Čerenkov photons in tissue limits the range of utility. The 
wavelength dependence of the spectrum is an important factor in this as well, with the 
blue/green wavelengths being very short pathlength (hundreds of microns), and the red and 
NIR wavelengths being significantly longer pathlengths (several mm to a cm).. These 
attenuation and low fluence issues will dominate what is likely possible and impossible in 
living tissues. 
Čerenkov luminescence imaging was faced with significant challenges in medical studies 
from the beginning. Recent studies continue to reform the directions that CLI appears to have, 
and its use will likely solve niche problems in medical imaging and dosimetry. The 
introduction of Čerenkov as a clinical imaging and therapy tool is promising and has unique 
strengths but also requires further development to optimize its value for each indication. 
Acknowledgments 
The authors would like to thank Esmaeil Jafari from Shiraz University of Medical Sciences 
and Prof. Majid Assadi, director of the Persian Gulf Nuclear Medicine Research Center for 
their assistance. This work has been supported by NIH research grant R01CA109558 (BWP). 
 
#242296 Received 2 Jun 2015; revised 15 Jul 2015; accepted 16 Jul 2015; published 28 Jul 2015 
(C) 2015 OSA 1 Aug 2015 | Vol. 6, No. 8 | DOI:10.1364/BOE.6.003053 | BIOMEDICAL OPTICS EXPRESS 3065 
